Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses: 2020-2024

Historic Operating Expenses for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $187.7 million.

  • Tango Therapeutics' Operating Expenses fell 10.67% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $187.7 million for FY2024, which is 24.53% up from last year.
  • Latest data reveals that Tango Therapeutics reported Operating Expenses of $187.7 million as of FY2024, which was up 24.53% from $150.7 million recorded in FY2023.
  • Tango Therapeutics' Operating Expenses' 5-year high stood at $187.7 million during FY2024, with a 5-year trough of $59.9 million in FY2020.
  • Over the past 3 years, Tango Therapeutics' median Operating Expenses value was $150.7 million (recorded in 2023), while the average stood at $158.1 million.
  • Data for Tango Therapeutics' Operating Expenses shows a peak YoY skyrocketed of 59.10% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Tango Therapeutics' Operating Expenses stood at $59.9 million in 2020, then spiked by 59.10% to $95.2 million in 2021, then surged by 42.74% to $135.9 million in 2022, then rose by 10.87% to $150.7 million in 2023, then rose by 24.53% to $187.7 million in 2024.